Literature DB >> 25502818

ADARs and the Balance Game between Virus Infection and Innate Immune Cell Response.

Sara Tomaselli1, Federica Galeano, Franco Locatelli, Angela Gallo.   

Abstract

All viruses that have dsRNA structures at any stages of their life cycle may potentially undergo RNA editing events mediated by the ADAR enzymes. Indeed, an increasing number of studies that describe A-to-I sequence changes in viral genomes and/or transcripts, consistent with ADAR deaminase activity, are reported. These modifications can appear either as hyperediting during persistent viral infections or as specific RNA editing events in viral dsRNAs. It is now well established that ADAR enzymes can affect viruses and viral interaction with the host cell in both an editing-dependent and -independent manner, with ADARs acting as pro- or anti-viral factors. Despite the discovery of editing events on viral RNAs dates back to thirty years ago, the biological consequences of A-to-I changes during viral infection is still far to be completely elucidated. In this review, past and recent studies on the importance of ADAR enzymes on several viruses will be examined.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25502818

Source DB:  PubMed          Journal:  Curr Issues Mol Biol        ISSN: 1467-3037            Impact factor:   2.081


  30 in total

Review 1.  The emerging role of RNA editing in plasticity.

Authors:  Joshua J C Rosenthal
Journal:  J Exp Biol       Date:  2015-06       Impact factor: 3.312

Review 2.  Emergency Services of Viral RNAs: Repair and Remodeling.

Authors:  Vadim I Agol; Anatoly P Gmyl
Journal:  Microbiol Mol Biol Rev       Date:  2018-03-14       Impact factor: 11.056

3.  ADAR2 Is Involved in Self and Nonself Recognition of Borna Disease Virus Genomic RNA in the Nucleus.

Authors:  Mako Yanai; Shohei Kojima; Madoka Sakai; Ryo Komorizono; Keizo Tomonaga; Akiko Makino
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

4.  Double-stranded RNA deaminase ADAR1 promotes the Zika virus replication by inhibiting the activation of protein kinase PKR.

Authors:  Shili Zhou; Chao Yang; Fanfan Zhao; Yanxia Huang; Yuxia Lin; Changbai Huang; Xiaocao Ma; Jingjie Du; Yi Wang; Gang Long; Junfang He; Chao Liu; Ping Zhang
Journal:  J Biol Chem       Date:  2019-10-21       Impact factor: 5.157

5.  Murine Hepatitis Virus nsp14 Exoribonuclease Activity Is Required for Resistance to Innate Immunity.

Authors:  James Brett Case; Yize Li; Ruth Elliott; Xiaotao Lu; Kevin W Graepel; Nicole R Sexton; Everett Clinton Smith; Susan R Weiss; Mark R Denison
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

Review 6.  Post-transcriptional regulation of LINE-1 retrotransposition by AID/APOBEC and ADAR deaminases.

Authors:  Elisa Orecchini; Loredana Frassinelli; Silvia Galardi; Silvia Anna Ciafrè; Alessandro Michienzi
Journal:  Chromosome Res       Date:  2018-02-02       Impact factor: 5.239

7.  Highly heterogeneous mutation rates in the hepatitis C virus genome.

Authors:  Ron Geller; Úrsula Estada; Joan B Peris; Iván Andreu; Juan-Vicente Bou; Raquel Garijo; José M Cuevas; Rosario Sabariegos; Antonio Mas; Rafael Sanjuán
Journal:  Nat Microbiol       Date:  2016-04-18       Impact factor: 17.745

Review 8.  A-to-I editing of coding and non-coding RNAs by ADARs.

Authors:  Kazuko Nishikura
Journal:  Nat Rev Mol Cell Biol       Date:  2015-12-09       Impact factor: 94.444

9.  Hepatitis B virus evades immune recognition via RNA adenosine deaminase ADAR1-mediated viral RNA editing in hepatocytes.

Authors:  Liyuan Wang; Yang Sun; Xiaojia Song; Zehua Wang; Yankun Zhang; Ying Zhao; Xueqi Peng; Xiaodong Zhang; Chunyang Li; Chengjiang Gao; Nailin Li; Lifen Gao; Xiaohong Liang; Zhuanchang Wu; Chunhong Ma
Journal:  Cell Mol Immunol       Date:  2021-07-12       Impact factor: 22.096

10.  Commentary on "Poor evidence for host-dependent regular RNA editing in the transcriptome of SARS-CoV-2".

Authors:  F Martignano; S Di Giorgio; G Mattiuz; S G Conticello
Journal:  J Appl Genet       Date:  2022-03-12       Impact factor: 2.653

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.